To further clarify the mechanism behind, in our next study, the PKM2 activity of all shikonin-treated bladder cancer cells will be measured, together with the expression level of PKM1, which might be upregulated during PKM2 inhibition and reduce cancer cell proliferation. The gene discussed is PKM; the disease is urinary bladder carcinoma.